Meanwhile, the Rapa-SLE-EV and SLE-EV treatment groups showed significantly reduced serum anti-dsDNA IgG levels in MRL/lpr mice compared with PBS-treated mice; the therapeutic effect of Rapa-SLE-EVs was more significant than that of SLE-EVs (Rapa-SLE-EV group vs. SLE-EV group, P < 0.05). This evidence concerns the gene TRERF1 and systemic lupus erythematosus.